The BAG2 and BAG5 proteins inhibit the ubiquitination of pathogenic ataxin3-80Q

References

• Durr A, Stevanin G, Cancel G, et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol 1996;39(4):490–9.
   PubMed Web of Science ®Google Scholar
• Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration. Annual review of neuroscience 2000;23(1):217–47.
   PubMedGoogle Scholar
• Gwinn-Hardy K, Singleton A, O’Suilleabhain P, et al. Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family. Arch Neurol 2001;58(2):296–9.
   PubMedGoogle Scholar
• Bettencourt C, Santos C, Coutinho P, et al. Parkinsonian phenotype in Machado-Joseph disease (MJD/SCA3): a two case report. BMC Neurol 2011;11:131–6.
   PubMedGoogle Scholar
• Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32. 1. Nature genetics 1994;8(3):221–8.
   PubMed Web of Science ®Google Scholar
• Durcan TM, Fon EA. Ataxin-3 and its e3 partners: implications for machadojoseph disease. Front Neurol 2013;4:46–51.
   PubMedGoogle Scholar
• Tsai YC, Fishmanm PS, Thakor NV, et al. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem 2003;278(24):22044–55.
   PubMed Web of Science ®Google Scholar
• Jana NR, Dikshit P, Goswami A, et al. Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J Biol Chem 2005;280(12):11635–40.
   PubMedGoogle Scholar
• Ying Z, Wang H, Fan H, et al. Gp78, an ER associated E3, promotes SOD1 and ataxin-3 degradation. Hum Mol Genet 2009;18(22):4268–81.
   PubMedGoogle Scholar
• Chai Y, Koppenhafer SL, Shoesmith SJ, et al. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Human molecular genetics 1999;8(4):673–82.
   PubMedGoogle Scholar
• Jana NR, Zemskov EA, Wang G-h, et al. Altered proteasomal function due to the expression of polyglutamine-expanded truncated Nterminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Human molecular genetics 2001;10(10):1049–59.
   PubMedGoogle Scholar
• Wang G-h, Sawai N, Kotliarova S, et al. Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23A and HHR23B. Human molecular genetics 2000;9(12):1795–803.
   PubMedGoogle Scholar
• Kabbage M, Dickman M. The BAG proteins: a ubiquitous family of chaperone regulators. Cellular and Molecular. Life Sciences 2008;65(9):1390–402.
   PubMed Web of Science ®Google Scholar
• Carrettiero DC, Hernandez I, Neveu P, et al. The cochaperone BAG2 sweeps paired helical filament-insoluble tau from the microtubule. The Journal of Neuroscience 2009;29(7):2151–61.
   PubMedGoogle Scholar
• Che X, Tang B, Wang X, et al. The BAG2 protein stabilises PINK1 by decreasing its ubiquitination. Biochemical and Biophysical Research Communications 2013;441(2):488–92.
   PubMedGoogle Scholar
• Arndt V, Daniel C, Nastainczyk W, et al. BAG-2 acts as an inhibitor of the chaperone-associated ubiquitin ligase CHIP. Molecular biology of the cell 2005;16(12):5891–900.
   PubMed Web of Science ®Google Scholar
• Dai Q, Qian S-B, Li H-H, et al. Regulation of the cytoplasmic quality control protein degradation pathway by BAG2. Journal of Biological Chemistry 2005;280(46):38673–81.
   PubMed Web of Science ®Google Scholar
• Kalia SK, Lee S, Smith PD, et al. BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron 2004;44(6):931–45.
   PubMed Web of Science ®Google Scholar
• Kalia LV, Kalia SK, Chau H, et al. Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). PloS one 2011;6(2):e14695.
   Google Scholar
• Beilina A, Rudenko IN, Kaganovich A, et al. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A 2014;111(7):2626–31.
   PubMedGoogle Scholar
• Nollen EAA, Brunsting JF, Song J, et al. Bag1 functions in vivo as a negative regulator of Hsp70 chaperone activity. Mol Cell Biol 2000;20(3):1083–8.
   PubMedGoogle Scholar
• Song, J, Takeda M, Morimoto RI. Bag1-Hsp70 mediates a physiological stress signalling pathway that regulates Raf-1/ERK and cell growth. Nature cell biology 2001;3(3):276–82.
   PubMedGoogle Scholar
• Elliott, E, Tsvetkov P, Ginzburg I. BAG-1 associates with Hsc70· Tau complex and regulates the proteasomal degradation of Tau protein. Journal of Biological Chemistry 2007;282(51):37276–84.
   PubMedGoogle Scholar
• Elliott, E, Laufer O, Ginzburg I. BAG‐1M is up‐regulated in hippocampus of Alzheimer's disease patients and associates with tau and APP proteins. Journal of neurochemistry 2009;109(4):1168–78.
   PubMedGoogle Scholar
• Orr, AL, Huang S, Roberts MA,et al. Sex-dependent effect of BAG1 in ameliorating motor deficits of Huntington disease transgenic mice. Journal of Biological Chemistry 2008;283(23):16027–36.
   PubMedGoogle Scholar
• Sroka, K, Voigt A, Deeg S, et al. BAG1 modulates huntingtin toxicity, aggregation, degradation, and subcellular distribution. J Neurochem 2009;111(3):801–7.
   PubMedGoogle Scholar
• Liman J,Sroka K,Dohm CP, et al. Modulation of huntingtin toxicity by BAG1 is dependent on an intact BAG domain. Molecules 2010;15(10):6678–87.
   Google Scholar
• Hasson SA,Kane LA,Yamano K, et al. High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy. Nature 2013;504(7479):291–5.
   PubMed Web of Science ®Google Scholar
• Chung KK,Dawson TM.Parkin and Hsp70 sacked by BAG5. Neuron 2004;44(6):899–901.
   PubMedGoogle Scholar
• Paulson HL, Perez MK,Trottier Y, et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997;19(2):333–344.
   PubMed Web of Science ®Google Scholar
• Goti D,Katzen SM,Mez J, et al. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci 2004;24(45):10266–79.
   PubMed Web of Science ®Google Scholar
• Matsumoto M,Yada M,Hatakeyama S, et al. Molecular clearance of ataxin-3 is regulated by a mammalian E4. EMBO J, 2004;23(3):659–69.
   PubMedGoogle Scholar